Is early-onset cancer an emerging global epidemic? Current evidence and future implications

T Ugai, N Sasamoto, HY Lee, M Ando… - Nature Reviews …, 2022 - nature.com
Over the past several decades, the incidence of early-onset cancers, often defined as
cancers diagnosed in adults< 50 years of age, in the breast, colorectum, endometrium …

Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges

A Elbehiry, E Marzouk, M Aldubaib, A Abalkhail… - Antibiotics, 2023 - mdpi.com
Helicobacter pylori (H. pylori) infection, which affects approximately half of the world's
population, remains a serious public health problem. As H. pylori infection leads to a number …

The global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019

J Zhao, L Xu, J Sun, M Song, L Wang, S Yuan… - BMJ …, 2023 - research.ed.ac.uk
Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to
2019 Page 1 Edinburgh Research Explorer The Global Trends in Incidence, Death, Burden and …

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

S Suzuki, T Gotoda, C Kusano, H Ikehara, R Ichijima… - Gut, 2020 - gut.bmj.com
Objective To date, no randomised trials have compared the efficacy of vonoprazan and
amoxicillin dual therapy with other standard regimens for Helicobacter pylori treatment. This …

[HTML][HTML] Helicobacter pylori infection: Beyond gastric manifestations

MLC Santos, BB de Brito, FAF da Silva… - World journal of …, 2020 - ncbi.nlm.nih.gov
Helicobacter pylori (H. pylori) is a bacterium that infects more than a half of world's
population. Although it is mainly related to the development of gastroduodenal diseases …

Antibody-conjugated liposomes loaded with indocyanine green for oral targeted photoacoustic imaging-guided sonodynamic therapy of Helicobacter pylori infection

R Wang, C Song, A Gao, Q Liu, W Guan, J Mei, L Ma… - Acta biomaterialia, 2022 - Elsevier
Helicobacter pylori is a causative factor of various gastrointestinal tract diseases. As clinical
antibiotic-based therapy for H. pylori infection might induce bacterial drug resistance, the in …

Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies

IA Cardos, DC Zaha, RK Sindhu, S Cavalu - Molecules, 2021 - mdpi.com
The prevalence of Helicobacter pylori infection remains significant worldwide and it depends
on many factors: gender, age, socio-economic status, geographic area, diet, and lifestyle. All …

Current state of knowledge regarding who high priority pathogens—Resistance mechanisms and proposed solutions through candidates such as essential oils: A …

M Romanescu, C Oprean, A Lombrea… - International journal of …, 2023 - mdpi.com
Combating antimicrobial resistance (AMR) is among the 10 global health issues identified
by the World Health Organization (WHO) in 2021. While AMR is a naturally occurring …

Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis

RC Du, YX Hu, Y Ouyang, LX Ling, JY Xu, R Sa… - …, 2024 - Wiley Online Library
Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin
(VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different …

Prevalence and associated risk factors of gastritis among patients visiting saint paul hospital millennium medical college, addis ababa, Ethiopia

ZT Feyisa, BT Woldeamanuel - Plos one, 2021 - journals.plos.org
Background The health of individuals is not only the absence of disease checked medically,
but also encompasses social and psychological aspects. Any departure from the state of …